Yield10 Bioscience, Inc. (YTENQ)
- Previous Close
0.0000 - Open
0.0150 - Bid 0.1500 x --
- Ask 0.1800 x --
- Day's Range
0.0150 - 0.0150 - 52 Week Range
0.0010 - 7.1599 - Volume
250 - Avg. Volume
247 - Market Cap (intraday)
10,390 - Beta (5Y Monthly) -0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-20.1400 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Yield10 Bioscience, Inc. operates as an agricultural bioscience company that focuses on commercializing products using the Camelina oilseeds in the United States. Its products include Camelina oil for production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA); and for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD), and sustainable aviation fuel (SAF). The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporated in 1992 and is headquartered in Woburn, Massachusetts. On December 6, 2024, Yield10 Bioscience, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
www.yield10bio.com29
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: YTENQ
View MorePerformance Overview: YTENQ
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: YTENQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: YTENQ
View MoreValuation Measures
Market Cap
10.39k
Enterprise Value
2.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.01
Price/Book (mrq)
--
Enterprise Value/Revenue
2.55
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-178.11%
Return on Equity (ttm)
--
Revenue (ttm)
750k
Net Income Avi to Common (ttm)
-12.7M
Diluted EPS (ttm)
-20.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
733k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.69M